Western Blot (WB)
((0. 01ug/ml) staining of Jurkat (A), HeLa (B) and NIH-3T3 (C) lysates (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence)
Goat CAPZB Polyclonal Antibody | anti-CAPZB antibody
Goat anti-CAPZB Antibody
Western Blot: Approx 30kDa band observed in lysates of cell lines Jurkat, HeLa and NIH-3T3 and approx 28kDa band observed in Mouse, Rat and Pig Heart lysates (calculated MW of 30.6kDa according to Human NP_004921.1 and 31.3kDa according to Mouse NP_001032850.1, and 30.6kDa according to Rat NP_001005903.1 and Pig NP_001106915.1]. Recommended concentration: 0.1-0.3ug/ml.
Western Blot (WB)
((0. 01ug/ml) staining of Jurkat (A), HeLa (B) and NIH-3T3 (C) lysates (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence)
Western Blot (WB)
((0. 01ug/ml) staining of Jurkat (A), HeLa (B) and NIH-3T3 (C) lysates (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence)
Western Blot (WB)
((0.1ug/ml) staining of Mouse (A), Rat (B) and Pig (C) Heart lysates (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.)
Western Blot (WB)
((0.1ug/ml) staining of Mouse (A), Rat (B) and Pig (C) Heart lysates (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.)
NCBI and Uniprot Product Information
NCBI Description
This gene encodes the beta subunit of the barbed-end actin binding protein, which belongs to the F-actin capping protein family. The capping protein is a heterodimeric actin capping protein that blocks actin filament assembly and disassembly at the fast growing (barbed) filament ends and functions in regulating actin filament dynamics as well as in stabilizing actin filament lengths in muscle and nonmuscle cells. A pseudogene of this gene is located on the long arm of chromosome 2. Multiple alternatively spliced transcript variants encoding different isoforms have been found.[provided by RefSeq, Aug 2013]
Uniprot Description
CAPZB: F-actin-capping proteins bind in a Ca(2+)-independent manner to the fast growing ends of actin filaments (barbed end) thereby blocking the exchange of subunits at these ends. Unlike other capping proteins (such as gelsolin and severin), these proteins do not sever actin filaments. Plays a role in the regulation of cell morphology and cytoskeletal organization. Belongs to the F-actin-capping protein beta subunit family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Actin-binding; Motility/polarity/chemotaxis
Chromosomal Location of Human Ortholog: 1p36.1
Cellular Component: actin cytoskeleton; actin filament; cytoskeleton; cytosol; F-actin capping protein complex; sarcomere
Molecular Function: actin binding; actin filament binding
Biological Process: actin cytoskeleton organization and biogenesis; barbed-end actin filament capping; blood coagulation; cell motility; cytoskeleton organization and biogenesis; negative regulation of filopodium formation; regulation of cell morphogenesis
Research Articles on CAPZB
Similar Products
Product Notes
The CAPZB capzb (Catalog #AAA421422) is an Antibody produced from Goat and is intended for research purposes only. The product is available for immediate purchase. The Goat anti-CAPZB Antibody reacts with Tested: Human, Mouse, Rat, Pig; Expected from sequence similarity: Human, Mouse, Rat, Dog, Pig, Cow and may cross-react with other species as described in the data sheet. AAA Biotech's CAPZB can be used in a range of immunoassay formats including, but not limited to, Peptide ELISA (EIA), Western Blot (WB). Peptide ELISA: Antibody detection limit dilution 1: 32000. Western Blot: Approx 30kDa band observed in lysates of cell lines Jurkat, HeLa and NIH-3T3 and approx 28kDa band observed in Mouse, Rat and Pig Heart lysates (calculated MW of 30.6kDa according to Human NP_004921.1 and 31.3kDa according to Mouse NP_001032850.1, and 30.6kDa according to Rat NP_001005903.1 and Pig NP_001106915.1]. Recommended concentration: 0.1-0.3ug/ml. Researchers should empirically determine the suitability of the CAPZB capzb for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. The amino acid sequence is listed below: NDLVEALKRK QQC. It is sometimes possible for the material contained within the vial of "CAPZB, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
